MAIA Biotechnology Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 13

Employees

  • Stock Symbol
  • MAIA

Stock Symbol

  • Share Price
  • $1.14
  • (As of Thursday Closing)

MAIA Biotechnology General Information

Description

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 444 West Lake Street
  • Suite 1700
  • Chicago, IL 60606
  • United States
+1 (312)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
ASE
Vertical(s)
Corporate Office
  • 444 West Lake Street
  • Suite 1700
  • Chicago, IL 60606
  • United States
+1 (312)

MAIA Biotechnology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MAIA Biotechnology Stock Performance

As of 19-Nov-2026, MAIA Biotechnology’s stock price is $1.14. Its current market cap is $70.4M with 61.8M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.14 $1.30 $0.87 - $3.19 $70.4M 61.8M 520K -$0.47

MAIA Biotechnology Financials Summary

As of 30-Sep-2026, MAIA Biotechnology has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 45,260 47,655 47,117 13,846
Revenue 0 0 0 0
EBITDA (25,728) (22,710) (23,573) (19,801)
Net Income (25,120) (22,396) (23,255) (19,773)
Total Assets 22,101 9,705 10,155 7,567
Total Debt 0 0 2,691 2,152
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MAIA Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MAIA Biotechnology‘s full profile, request access.

Request a free trial

MAIA Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commerci
Biotechnology
Chicago, IL
13 As of 2025

Needham, MA
 

Dallas, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MAIA Biotechnology Competitors (8)

One of MAIA Biotechnology’s 8 competitors is Candel Therapeutics, a Formerly VC-backed company based in Needham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Candel Therapeutics Formerly VC-backed Needham, MA
Lantern Pharma Formerly VC-backed Dallas, TX
Black Diamond Therapeutics Formerly VC-backed Cambridge, MA
Pyxis Oncology Formerly VC-backed Boston, MA
Corvus Pharmaceuticals Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 8 competitors. Get the full list »

MAIA Biotechnology Patents

MAIA Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024370164-A1 Telomere-targeting phosphatidyl-thio conjugates Pending 29-Oct-2023
EP-4798601-A1 Telomere-targeting phosphatidyl-thio conjugates Pending 29-Oct-2023
US-20250136633-A1 Telomere-targeting phosphatidyl-thio conjugates Pending 29-Oct-2023
WO-2025096481-A1 Telomere-targeting phosphatidyl-thio conjugates Inactive 29-Oct-2023
WO-2025090539-A1 Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab Inactive 22-Oct-2023 A61P35/00
To view MAIA Biotechnology’s complete patent history, request access »

MAIA Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MAIA Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MAIA Biotechnology‘s full profile, request access.

Request a free trial

MAIA Biotechnology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view MAIA Biotechnology’s complete esg history, request access »

MAIA Biotechnology FAQs

  • When was MAIA Biotechnology founded?

    MAIA Biotechnology was founded in 2018.

  • Where is MAIA Biotechnology headquartered?

    MAIA Biotechnology is headquartered in Chicago, IL.

  • What is the size of MAIA Biotechnology?

    MAIA Biotechnology has 13 total employees.

  • What industry is MAIA Biotechnology in?

    MAIA Biotechnology’s primary industry is Biotechnology.

  • Is MAIA Biotechnology a private or public company?

    MAIA Biotechnology is a Public company.

  • What is MAIA Biotechnology’s stock symbol?

    The ticker symbol for MAIA Biotechnology is MAIA.

  • What is the current stock price of MAIA Biotechnology?

    As of 19-Nov-2026 the stock price of MAIA Biotechnology is $1.14.

  • What is the current market cap of MAIA Biotechnology?

    The current market capitalization of MAIA Biotechnology is $70.4M.

  • Who are MAIA Biotechnology’s competitors?

    Candel Therapeutics, Lantern Pharma, Black Diamond Therapeutics, Pyxis Oncology, and Corvus Pharmaceuticals are some of the 8 competitors of MAIA Biotechnology.

  • What is MAIA Biotechnology’s annual earnings per share (EPS)?

    MAIA Biotechnology’s EPS for 12 months was -$0.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process